Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.